BioStem Technologies has appointed Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee. The appointment, effective March 18, 2026, brings nearly three decades of financial leadership to the MedTech company, which focuses on placental-derived products for advanced wound care. Ungrodt spent her career as a senior partner at Ernst & Young, advising life sciences companies on public offerings, business combinations, risk assessment, and regulatory compliance. She is qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that Ungrodt's appointment comes as the company undertakes business expansion beyond chronic wound care and plans to raise its profile in public markets in 2026. He highlighted her twenty-nine years of life sciences accounting experience at Ernst & Young, track record advising more than thirty IPOs, and deep regulatory expertise as valuable additions to board governance during this pivotal time. BioStem is an emerging leader in placental and umbilical cord–derived tissue products, with a proprietary allograft portfolio derived from donated birth tissue. The company continues research to expand scientific understanding and bring new products to market.
As Audit Committee Chair, Ungrodt will oversee the company's financial reporting, internal controls, and risk management practices. Her prior experience includes serving as Chair of the Audit Committee for Feeding San Diego, where she provided accounting, budgeting, and risk assessment guidance for over a decade. She is also an Advisory Board Member for Life Science Cares. During her tenure at EY, Ungrodt served more than 70 companies across the Life Sciences sector. Ungrodt expressed excitement about joining BioStem's board, noting the company's strong momentum in the chronic wound market and recent expansion into acute applications of its technologies. She stated that these technologies have potential to improve patient outcomes as the company continues to scale and innovate.
Ungrodt replaces former board member Brandon Poe, who accepted the role of BioStem's chief financial officer in August 2025. Poe brings more than 25 years of finance leadership experience across healthcare and life sciences sectors and served on BioStem's Board of Directors for three years before joining the organization. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks, established in compliance with current Good Tissue Practices and current Good Manufacturing Processes. The company's portfolio includes its Neox, Clarix, VENDAJE, and American Amnion product lines. More information about the company is available at https://www.biostemtechnologies.com.
This appointment signals BioStem's commitment to strengthening financial oversight and corporate governance as it navigates growth and potential public market activities. For investors and industry observers, the addition of a seasoned financial expert with specific life sciences IPO experience suggests BioStem may be preparing for significant corporate milestones, possibly including uplisting to a major exchange or pursuing additional capital raises. The move also reflects the increasing regulatory scrutiny in the MedTech sector, particularly for companies working with biological tissues, making Ungrodt's compliance expertise particularly valuable. Her background in risk assessment could help BioStem manage the complexities of expanding its product applications while maintaining rigorous quality standards. The company's focus on placental-derived products represents a growing segment of regenerative medicine, and enhanced financial leadership could support both clinical research initiatives and commercial expansion.
